Gene Transfer Technologies Market Size was valued at USD 3.8 Bn in 2024 and is predicted to reach USD 10.1 Bn by 2034 at a 10.7% CAGR during the forecast period for 2025-2034.
The market for gene transfer technologies (GTT) is the area of biotechnology that focuses on introducing genetic material into cells to improve biological processes, treat or prevent diseases, or increase agricultural qualities. In gene therapy, altered genes are inserted into a patient's cells to treat hereditary illnesses or strengthen immune responses. These technologies are essential to this process. The growing incidence of genetic abnormalities, the emergence of customized treatment, and the quick speed of biotechnology development are the main factors propelling the market for gene transfer technologies. The potential of gene therapies to heal diseases that were previously incurable has drawn considerable attention from government agencies, researchers, and pharmaceutical corporations. Furthermore, the popularity of recent well-known gene therapy treatments has increased trust in the area. In the upcoming years, the gene transfer technologies market is expected to increase significantly as scientific discoveries continue to be made and gene transfer methods become more affordable.
Additionally, the adoption of gene transfer technologies in the market is anticipated to be fueled by the growing applications in cancer immunotherapy and vaccine development in the upcoming years. However, major obstacles to the gene transfer technologies market include high development costs, strict regulations, and moral dilemmas with genetic engineering. In addition, there are substantial obstacles due to the technical difficulties in efficiently transferring the drug to the target cells without causing negative reactions.
Competitive Landscape
Some of the Major Key Players in the Gene Transfer Technologies Market are
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Merck KgaA
- Qiagen
- Sartorius AG
- Bio-Rad Laboratories Inc.
- Revvity
- Agilent Technologies, Inc.
- Genscript
- Bio-Techne
- Lonza
- Takara Bio, Inc.
- Promega Corporation
- Oxford Biomedica plc
- MaxCyte
- Others
Market Segmentation:
The gene transfer technologies market is segmented based on product, mode, method, application, and end-user. Based on product, the market is segmented into reagents, kits, and assays, consumables, instruments, and others. By mode, the market is segmented into viral vectors (retroviruses, adenoviruses, adeno-associated viruses, others), non-viral vectors (chemical methods, liposome-mediated, calcium phosphate, DEAE-dextran, cationic polymers, others), and physical methods (electroporation, microinjection, gene guns, other physical methods). By method, the market is segmented into in vivo, ex vivo and in vitro. By application, the market is segmented into therapeutic applications (gene therapy, cell therapy, vaccines, others), research applications (drug discovery & development, infectious diseases, genetic & neurological disorders, autoimmune diseases, others) and others. By end-user, the market is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and others.
Based on the Mode, the Viral Vectors Segment is Accounted as A Major Contributor to the Gene Transfer Technologies Market
The viral vectors is expected to hold a major global gene transfer technologies market share in 2024 spurred by developments in viral vector production (including automation and scalable production methods), improvements in cell-based therapeutics, and the growing use of lentiviruses, retroviruses, and Adeno-associated viruses (AAVs) for a range of therapeutic purposes. Further expansion in the industry is anticipated as a result of increased investment in viral vector technology. Moreover, the growing incidence of rare and chronic illnesses promotes the use of viral vectors. On the other hand, the possibility of non-viral systems for precise targeted genetic alterations without the hazards associated with viral vectors is another reason why non-viral vectors are rapidly increasing market dominance. This element propels the non-viral segment's expansion.
In Vivo Segment to Witness Growth at a Rapid Rate
In 2024, the in vivo category led the gene transfer technologies market. The development of vector technologies, especially viral vectors like lipid nanoparticle (LNP) systems and adeno-associated viruses (AAVs), the rising incidence of chronic illnesses and genetic disorders that may increase the need for novel therapeutic approaches, and the growing use of LNPs in mRNA vaccines are the primary factors propelling the in vivo segment's growth. The segment's growth is also being greatly aided by increased government and pharmaceutical company investment, as well as regulatory backing for novel gene therapies.
In the Region, the North American Gene Transfer Technologies Market Holds a Significant Revenue Share
The North American gene transfer technologies market is expected to register the highest market share in revenue in the near future. The region's increasing need for gene transfer technologies coincides with a notable increase in active clinical trials assessing the efficacy of gene treatments for the treatment of rare diseases, cancer, genetic mutations, and inherited problems in the US. In addition, Asia Pacific is projected to grow rapidly in the global Gene Transfer Technologies market. The pharmaceutical and biotechnology industries' growing investment and research funding to develop the healthcare sector is probably going to propel the region's market expansion. Additionally, growing R&D into cutting-edge treatments and increased cooperation between regional biotech and international businesses are fueling demand and accelerating market expansion.
Recent Development:
- September 2024: Cytiva expanded the GenVox-ILM product line to expedite the production of mRNA and siRNA vaccines with the introduction of the RNA delivery LNP kit, which is intended for use with the NanoAssembl Ignite and Ignite+ systems.
- June 2024: Following Syncona's successful merger of Freeline and SwanBio, the merged business is now known as Spur Therapeutics. Additionally, Syncona has pledged USD 50 million to support the new business's gene therapy research.
- March 2024: Sartorius expanded its plasmid inventory to accommodate a range of AAV serotypes by introducing RPLUS, AAV-RC2, a Bercar plasmid for adeno-associated virus vector 2 (AAV2) manufacturing.
Gene Transfer Technologies Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 3.8 Bn |
|
Revenue Forecast In 2034 |
USD 10.1 Bn |
|
Growth Rate CAGR |
CAGR of 10.7% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, By Mode, By Method, By Application, By End-User and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Thermo Fisher Scientific Inc., Danaher Corporation, Merck KgaA, Qiagen, Sartorius AG, Bio-Rad Laboratories Inc., Revvity, Agilent Technologies, Inc., Genscript, Bio-Techne, Lonza, Takara Bio, Inc., Promega Corporation, Oxford Biomedica plc, MaxCyte, and other prominent players. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
